Vigilant Capital Management’s Fate Therapeutics FATE Stock Holding History

Vigilant Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,000	Closed	-$16K	–	468
2019 Q3	$16K	Hold	1,000	–	–	﹤0.01%	330
2019 Q2	$20K	Hold	1,000	–	–	﹤0.01%	322
2019 Q1	$18K	Hold	1,000	–	–	﹤0.01%	334
2018 Q4	$13K	Hold	1,000	–	–	﹤0.01%	354
2018 Q3	$16K	Hold	1,000	–	–	﹤0.01%	373
2018 Q2	$11K	Hold	1,000	–	–	﹤0.01%	408
2018 Q1	$10K	Hold	1,000	–	–	﹤0.01%	364
2017 Q4	$6K	Hold	1,000	–	–	﹤0.01%	361
2017 Q3	$4K	Hold	1,000	–	–	﹤0.01%	283
2017 Q2	$3K	Hold	1,000	–	–	﹤0.01%	258
2017 Q1	$5K	Buy	+1,000	New	+$3.66K	﹤0.01%	258

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vigilant Capital Management's FATE Position: Q4 2019 in Review

Vigilant Capital Management sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 1,000 shares — an estimated $16K sold.

Vigilant Capital Management first reported a position in FATE in Q1 2017 and held it in 11 quarters. The position peaked at $20K in Q2 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

Vigilant Capital Management reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
Vigilant Capital Management sold 1,000 Fate Therapeutics shares in Q4 2019, an estimated $16K.
Vigilant Capital Management first reported a position in Fate Therapeutics in Q1 2017 and held it in 11 quarters.
Vigilant Capital Management's Fate Therapeutics position peaked at $20K in Q2 2019.
147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Vigilant Capital Management's 13F filing for Q4 2019, filed 17 Jan 2020.